Industrials stocks · Micro cap · NSE
Shaily Engineering Plastics Limited is India’s largest exporter of plastics components, established in 1987. The company provides end-to-end solutions in plastic products and services, operating 7 facilities in Gujarat with over 200 injection molding machines and 2,000+ employees.
SMA20 -4.9% / mo · MACD +
Latest mapped FPI equity flow was not positive. View sector evidence
Adjusted completed-session prices, rebased to 100
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Revenue +13.8% · PAT +17.1% YoY
Price trend and sector-relative-strength timing.
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Financial-only signal; management claim evidence is not sufficient yet.
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Rev +14% YoY · PAT +17% YoY · margin expansion · +19% QoQ
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹281 Cr | +13.8% | +18.6% |
| EBITDA | ₹83 Cr | +22.1% | +25.8% |
| Operating margin | 30.0% | +200 bps | +200 bps |
| PAT | ₹48 Cr | +17.1% | +20.0% |
| PAT margin | 17.1% | +48 bps | +20 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Updated 19/10/2026
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Trend is weak — long-term uptrend intact. RSI 48.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
U-Score 56 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Top U-Score contributors and drags from the latest stored fundamentals.
Capital-intensive execution stories need cash-flow and balance-sheet checks alongside valuation.
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
12 stored score snapshots. Latest stored move: +0 points.
Business-comparable peers in Industrials — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Growth engines, risks, management commitments and evidence-backed delivery
Consolidated Q4FY26 revenue grew 9% YoY to Rs. 236.8 Cr, with EBITDA up 27% to Rs. 69.3 Cr and PAT up 40% to Rs. 40.2 Cr. For FY26, revenue rose 26% to Rs. 990.7 Cr, EBITDA 61% to Rs. 287.7 Cr, and PAT 83% to Rs. 169.9 Cr, driven by strong healthcare segment performance.
The company delivered robust FY26 growth, primarily driven by the high-margin healthcare segment, which more than offset weakness in consumer. Strategic diversification into semiconductor trays and a significant pharma order book provide future visibility. Margins expanded significantly, and capital efficiency improved.
Latest issuer-disclosed distribution across 3 reported categories.
Successful commercial launch of Shaily Harmony and Shaily Neo pens for Semaglutide; customer launched Semaglutide pens in Canada. EMA approval received by customer for Teriparatide.
Received an order worth Rs. 423 crore from a large domestic pharma company for supply of pen injectors over four years.
Commenced commercial supplies to a consumer electronics customer. Signed agreement with a Korean company for manufacture & supply of semiconductor trays.
Business awarded from new customers for power tool components and LED light components.
19 new machines successfully installed as part of the expansion of the plant during Q2 FY26.
Successful installation of Plant & Machinery supplied by customer for the manufacture of Eye Applicators.
Operates 7 facilities in Gujarat (6 for plastic, 1 for steel furniture) with over 200 injection molding machines.
Improved traction in the healthcare segment has been the key driver for the overall growth of the business.
Actively diversifying its revenue base into high-growth, precision-intensive adjacencies like Consumer Electronics & Semiconductor Trays.
Enabling resolution for fund raise (up to Rs. 500 Cr) provides flexibility to capitalize on growing opportunities in existing and expanding markets.
Weaker market demand for Home Furnishings across Europe & USA.
Volume of Polymers Processed decreased by 28% YoY in Q4FY26 and 4% YoY in FY26.
Consumer segment revenue declined 9% in FY26 and 31% in Q4FY26, impacted by weaker demand in Europe & USA.
Successful ramp-up and profitability of new ventures in consumer electronics and semiconductor trays are crucial for diversification strategy.
Trade Receivables increased from Rs. 171.7 Cr in Mar-25 to Rs. 214.8 Cr in Mar-26, requiring careful monitoring.
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
The presentation provides both Q4 and full-year (FY26 vs FY25) consolidated and standalone results. Q4 shows recent momentum, while FY26 provides a comprehensive view of annual performance and strategic shifts, especially in segment mix.
Q4FY26: Rs. 236.8 Cr (+9% YoY); FY26: Rs. 990.7 Cr (+26% YoY).
Q4FY26: 29.3% (+420 bps YoY); FY26: 29.0% (+630 bps YoY).
Q4FY26: Rs. 40.2 Cr (+40% YoY); FY26: Rs. 169.9 Cr (+83% YoY).
Received an order worth Rs. 423 crore from a large domestic pharma company for supply of pen injectors over a period of four years.
Management states, 'Beyond healthcare, Shaily is actively diversifying its revenue base into high-growth, precision-intensive adjacencies – Consumer Electronics & Semiconductor Trays.'
Management views Shaily as 'evolving into a diversified, IP-led global manufacturing platform,' with fund-raise providing flexibility for growth.
Appointed Mr. Joe Kam as COO (Healthcare) to drive healthcare business growth, bringing over 20 years of global manufacturing and operations leadership.
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Healthcare Revenue Growth | FY26 Healthcare revenue grew 139% YoY to Rs. 392.8 Cr. | Continued strong growth and new customer additions in GLP-1 and other therapies. |
| New Order Inflows & Execution | Rs. 423 Cr pen injector order over four years. | Timely execution of large pharma orders and new business confirmations in industrial and electronics. |
| Machine Utilization & Polymer Volume | Machine utilization at 47.6% (FY26), polymer volume processed declined 4% (FY26). | Improvement in polymer volume processed and further increase in machine utilization rates. |
| Working Capital Efficiency | Trade Receivables at Rs. 214.8 Cr (Mar-26). | Stable or improving receivables days and inventory turnover as business scales. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 93rd percentile of the scored universe and 92nd percentile within Industrials. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
overall median 67 · Industrials: 92nd pctile, median 68 · Micro: 86th pctile, median 73
107 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Latest exchange and company disclosures found within the past two years.
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse